| Literature DB >> 22074594 |
Jason E McDermott1, Harish Shankaran, Amie J Eisfeld, Sarah E Belisle, Gabriele Neuman, Chengjun Li, Shannon McWeeney, Carol Sabourin, Yoshihiro Kawaoka, Michael G Katze, Katrina M Waters.
Abstract
BACKGROUND: Understanding host response to influenza virus infection will facilitate development of better diagnoses and therapeutic interventions. Several different experimental models have been used as a proxy for human infection, including cell cultures derived from human cells, mice, and non-human primates. Each of these systems has been studied extensively in isolation, but little effort has been directed toward systematically characterizing the conservation of host response on a global level beyond known immune signaling cascades.Entities:
Mesh:
Year: 2011 PMID: 22074594 PMCID: PMC3229612 DOI: 10.1186/1752-0509-5-190
Source DB: PubMed Journal: BMC Syst Biol ISSN: 1752-0509
Figure 1Functional similarity between VN1203-infected Calu-3 cells and macaques. Differentially expressed genes in each treatment were analyzed for their functional enrichment in GO biological process terms. Treatments (system, virus and time combinations) were clustered together based on the functional enrichment scores for a set of 76 GO terms using hierarchical clustering. A partitioning that results in 5 clusters is illustrated using distinct colors for each of the clusters. Treatments are projected on to the first three coordinates obtained via principal component analysis of the matrix of enrichment scores, and are colored based on their cluster membership. Lines indicate the temporal progression of VN1203 infection in each system. Treatments present in each cluster are listed at right.
Functional similarity between in vitro and in vivo models of influenza infection.
| Biological Process | Enrichment Scorea | ||||
|---|---|---|---|---|---|
| Calu3-early | Calu3-late | Both-mid | Mac-early | Mac-late | |
| muscle contraction/circulatory system process | 0.16 | ||||
| chemotaxis | 0.18 | ||||
| response to virus/innate immune response | 0.24 | ||||
| response to external stimulus/locomotion | 0.29 | ||||
| muscle system process/smell perception | 0.20 | 0.95 | |||
| mRNA processing/translation | 0.18 | 0.73 | |||
| regulation of immune response | 0.21 | 1.04 | |||
| mitosis/cell cycle phase | 0.24 | 0.78 | |||
| cytokine production/secretion | 0.19 | 0.80 | 1.05 | ||
| cell adhesion/division/microtubule-based process | 0.30 | 0.80 | 0.95 | ||
| transcription reguln/protein degradation/anti-apoptosis | 0.17 | 0.62 | 1.07 | 0.88 | |
| proteasomal protein catabolic process | 0.23 | 0.69 | 0.98 | 0.93 | |
| regulation of leukocyte proliferation | 0.18 | 1.09 | 0.73 | ||
a The geometric mean enrichment score was calculated for each treatment cluster-GO group combination. Enrichment score >1.3 corresponds to p < 0.05.
*bold type indicates statistically significant values
Figure 2Cross-coexpression analysis of avian influenza response in Calu-3, mouse and macaque. The heatmap shows the cross-coexpression matrix of homologs in the Calu-3, mouse and macaque datasets representing the mean coexpression of each pair of genes (columns indicate one gene of a pair and rows indicate the other) from all three sets. A dendrogram from hierarchical clustering is shown at left and was used to divide the genes into six clusters (indicated by bars at right). Plots show the expression levels (log2 fold-change versus mock infected) of all genes in each of the four largest clusters (grey lines) and cluster means are represented by colored lines for Calu-3 (red), macaque (blue) and mouse (green). Significantly enriched functions for each cluster are listed on the right. This figure shows that our cross-coexpression analysis identifies groups of genes that are coexpressed in each organism but have different dynamics in each.
Figure 3Overview of cross-predictive modeling approach. To allow cross-predictive comparison of response to influenza infection between Calu-3 and in vivo systems, we first clustered the Calu-3 expression data (1) from two similar experiments using hierarchical clustering. The clusters (colored boxes) are used to summarize system behavior and serve as the 'targets' for inference. A regulatory influence network is inferred (2) that relates the expression of inferred regulatory influences (X) to the mean expression (Y) of each target cluster (i). Cross-validation (3) is carried out by leaving out expression data from each time point in turn, inferring a model, then using the model to predict the behavior of each cluster for the left out time point. Performance of the model is assessed as the gene-weighted mean correlation between the predicted (Y) and observed (O) expression of all clusters. Finally, the weights from the Calu-3 model are applied to the macaque/mouse data and performance assessed by evaluating the gene-weighted mean correlation between the predicted expression and the observed expression in macaque/mouse for each cluster.
Figure 4Performance of Calu-3 regulatory influence model in cross-validation. A. Performance of inferred models with varying numbers of target clusters. The cross-validation approach described was used to infer models based on varying numbers of target clusters (X axis) from the Calu-3 response to avian influenza infection. Performance is expressed as the mean correlation (Y axis) of predicted expression to the observed expression normalized to the number of genes in each target. B. Performance inferred model at predicting expression of co-expressed clusters. The cross-validation approach described was used to infer a model based on ten co-expressed clusters (X axis) from the Calu-3 response to avian influenza infection. Performance is expressed as the mean correlation (Y axis) of predicted expression to the observed expression for each cross-validated time point. Details about each cluster are provided in Table 2. C. Predicted and observed expression patterns for an innate immune-related cluster. The predicted expression levels (green line) from cross-validation are shown over the six time points post-infection versus the observed mean expression (red line) for cluster 8 (see Table 2).
Functional enrichment of Calu-3 clusters.
| Cluster | Top biological functions enrichment within each cluster | Predictive abilitya | ||||
|---|---|---|---|---|---|---|
| Functional Pathways | p-valueb | # molecules | Calu-3 | Macaque | Mouse | |
| 1 | None | 0.89* | 0.23 | 0.98* | ||
| 2 | cell surface receptor linked signal transduction | 1.56E-02 | 6 | 0.88* | -0.44 | 0.28 |
| activation of eukaryotic cells | 1.56E-02 | 9 | ||||
| developmental process of antigen presenting cells | 1.56E-02 | 5 | ||||
| aggregation of blood cells | 3.09E-02 | 4 | ||||
| growth of leukocytes | 3.09E-02 | 4 | ||||
| replication of virus | 3.09E-02 | 6 | ||||
| 3 | binding of blood cells | 5.22E-07 | 16 | 0.96* | 0.44 | 0.98* |
| activation of granulocytes | 5.28E-07 | 11 | ||||
| stimulation of normal cells | 6.52E-07 | 13 | ||||
| inflammatory response | 6.56E-07 | 23 | ||||
| maturation of leukocytes | 6.98E-07 | 14 | ||||
| chemotaxis of cells | 9.01E-07 | 20 | ||||
| activation of monocytes | 9.65E-07 | 9 | ||||
| activation of phagocytes | 9.65E-07 | 13 | ||||
| activation of T lymphocytes | 1.09E-06 | 16 | ||||
| immune response | 2.82E-06 | 28 | ||||
| 4 | developmental process of blood cells | 2.38E-04 | 41 | 0.99* | -0.13 | -0.99* |
| function of lymphatic system cells | 1.95E-03 | 5 | ||||
| recruitment of normal cells | 4.40E-03 | 14 | ||||
| differentiation of lymphocytes | 4.47E-03 | 20 | ||||
| function of leukocytes (including function of granulocytes) | 5.51E-03 | 9 | ||||
| quantity of leukocytes | 5.76E-03 | 25 | ||||
| 5 | development of intercellular junctions | 8.80E-04 | 10 | 0.83 | -0.21 | 0.92* |
| 6 | cell division process | 2.98E-03 | 253 | 0.96 | 0.25 | -0.97* |
| metabolism of carbohydrate | 3.52E-02 | 80 | ||||
| transactivation | 3.52E-02 | 127 | ||||
| cell death of connective tissue cells | 3.83E-02 | 66 | ||||
| modification of DNA | 5.02E-02 | 58 | ||||
| 7 | secretion of cytokine/recognition of cells | 2.97E-02 | 1 | 0.64 | 0.32 | 0.58 |
| methylation of protein or DNA | 2.97E-02 | 1 | ||||
| 8 | accumulation of calcium | 3.13E-02 | 6 | 0.97* | 0.68* | -0.86 |
| contraction of tissue | 3.69E-02 | 16 | ||||
| neurotransmission | 3.78E-02 | 20 | ||||
| blood pressure | 3.78E-02 | 13 | ||||
| response of cells | 3.78E-02 | 24 | ||||
| synthesis of cyclic AMP | 3.78E-02 | 7 | ||||
| 9 | None | 0.72 | 0.25 | 0.86 | ||
| 10 | transcription | 1.67E-08 | 150 | 0.99* | 0.72* | 0.33 |
| protein kinase cascade (including IKKB/NFkB cascades) | 4.25E-03 | 33 | ||||
| activation of cyclin-dependent protein kinase | 5.06E-03 | 11 | ||||
| developmental process of organism | 1.62E-02 | 81 | ||||
| cell cycle progression | 2.79E-02 | 67 | ||||
| activation of protein | 4.00E-02 | 20 | ||||
a asterisk indicates statistical significance versus random for predictive ability
b Benjamini-Hochberg adjusted
Genes exhibiting consistent relationships with inferred regulatory influences between the Calu-3 model, macaque, and mouse response data.
| Symbol | ID | Description | Macaquea | Mouse |
|---|---|---|---|---|
| ABI3 | NM_016428 | ABI gene family, member 3 | ||
| MXD1 | NM_002357 | MAX dimerization protein 1 | 0.53 | |
| ALOX5 | NM_000698 | arachidonate 5-lipoxygenase | ||
| COL4A3 | NM_000091 | collagen, type IV, alpha 3 (Goodpasture antigen) | ||
| C1QTNF3 | NM_181435 | C1q and tumor necrosis factor related protein 3 | ||
| CH25H | NM_003956 | cholesterol 25-hydroxylase | ||
| FOS | NM_005252 | v-fos FBJ murine osteosarcoma viral oncogene homolog | ||
| TNFSF13B | NM_006573 | tumor necrosis factor (ligand) superfamily, member 13b | ||
| IL1R2 | NM_004633 | interleukin 1 receptor, type II | ||
| CD86 | NM_006889 | CD86 molecule | ||
| TNFAIP3 | NM_006290 | tumor necrosis factor, alpha-induced protein 3 | 0.70 | |
| ASCL2 | NM_005170 | achaete-scute complex homolog 2 (Drosophila) | ||
| IRX4 | NM_016358 | iroquois homeobox 4 | ||
| BATF2 | NM_138456 | basic leucine zipper transcription factor, ATF-like 2 | ||
| SCNN1G | X87160 | sodium channel, nonvoltage-gated 1, gamma | ||
| PARP11 | NM_020367 | poly (ADP-ribose) polymerase family, member 11 | 0.83 | |
| CMTM2 | NM_144673 | CKLF-like MARVEL transmembrane domain containing 2 | ||
| ADM | NM_001124 | Adrenomedullin | 0.77 | |
| PRSS12 | NM_003619 | protease, serine, 12 (neurotrypsin, motopsin) | ||
| USP18 | NM_017414 | ubiquitin specific peptidase 18 | ||
| PI3 | NM_002638 | peptidase inhibitor 3, skin-derived (SKALP) | ||
| IL29 | NM_172140 | interleukin 29 (interferon, lambda 1) | ||
| UPP1 | NM_181597 | uridine phosphorylase 1 | 0.84 | |
| INDO | NM_002164 | indoleamine-pyrrole 2,3 dioxygenase | ||
| LDHC | NM_002301 | lactate dehydrogenase C | ||
| CXCL10 | NM_001565 | chemokine (C-X-C motif) ligand 10 | ||
| RND1 | NM_014470 | Rho family GTPase 1 | ||
| IFIT2 | NM_001547 | interferon-induced protein with tetratricopeptide repeats 2 | ||
| IFIT1 | NM_001548 | interferon-induced protein with tetratricopeptide repeats 1 | ||
| IFIT3 | NM_001549 | interferon-induced protein with tetratricopeptide repeats 3 | ||
| ATF3 | NM_004024 | activating transcription factor 3 | ||
| OASL | NM_003733 | 2'-5'-oligoadenylate synthetase-like | ||
| CCL4 | NM_002984 | chemokine (C-C motif) ligand 4 | ||
| JUNB | NM_002229 | jun B proto-oncogene | 0.66 | |
| MX2 | NM_002463 | myxovirus (influenza virus) resistance 2 | ||
| XAF1 | NM_017523 | XIAP associated factor-1 | ||
| IL6 | NM_000600 | interleukin 6 (interferon, beta 2) | ||
| RSAD2 | NM_080657 | radical S-adenosyl methionine domain containing 2 | ||
| OAS2 | NM_016817 | 2'-5'-oligoadenylate synthetase 2, 69/71kDa | 0.84 |
a Xpred scores from Calu-3 model cross-predictions in macaque and mouse. Bold indicates statistical significance (p-value < 0.05)
Figure 5Top Canonical Pathway: Role of hypercytokinemia and hyperchemokinemia in influenza. A. Integrated Pathway Analysis (IPA) canonical pathway map of the most significant pathway enriched in the set of highly predicted genes (Table 3). Shown in yellow are the highly cross-predicted genes. B. Expression patterns of highly predicted genes in Calu-3 cells and macaques. Dashed blue lines (CXCL10, IL29) indicate an earlier response and red lines (IL6, CCL4) are later in the Calu-3 infection.
Figure 6Expression of highly predicted gene clusters. A. The cross-prediction approach was taken to predict expression (green line) of the proinflammatory cytokine IL-6. The observed expression is shown as a red line. B. Behavior of RSAD2 and OASL in macaque based on the model inferred from Calu-3 expression data. This figure shows that the in vitro Calu-3 system can be highly informative about the behavior of certain genes in a whole macaque infection.
Top inferred regulatory influences for highly cross-predicted genes.
| Predicted Regulatory Influencea | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gene Symbol | GTF2B | ATF4 | IFI44 | IFNGR2 | FOXE1 | BRF1 | ELF1 | ELF2 | IRF2 |
| 29 | 23 | 20 | 17 | 12 | 11 | 10 | 11 | 10 | |
"+" indicates positive and "-" negative regulation. Genes that are only regulated by one of these regulators are not shown.